Novo Nordisk announced positive results from its PIONEER TEENS phase 3a trial, where oral semaglutide significantly reduced blood sugar (HbA1c) by 0.83% compared to placebo in patients aged 10-17 with type 2 diabetes. This drug demonstrated a safety profile consistent with previous trials and could become the first oral GLP-1 treatment approved for young patients, addressing the rising prevalence of youth-onset type 2 diabetes. Novo Nordisk plans to seek regulatory approval in the US and EU later this year, potentially expanding treatment options beyond metformin and insulin, which have limitations in this age group.
The European Commission has approved Novo Nordisk's Wegovy pill, the first oral GLP-1 receptor agonist for weight management across the EU. This approval covers adults with obesity or overweight with related health issues and follows positive clinica...
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
Vivani Medical is developing a semaglutide implant aimed at improving long-term adherence to GLP-1 treatments like Wegovy and Ozempic, which help with obesity and diabetes. The implant, designed to be replaced biannually or annually, could reduce sid...
